Product logins

Find logins to all Clarivate products below.


Ekaterina Kotelnikova

Associate Director for Discovery and Translational Science Consulting

Ekaterina is a highly experienced professional in bioinformatics consulting, with over 20 years of expertise in bioinformatics and systems biology. She holds a Ph.D. in molecular evolution and has a background in biophysics. Throughout her career, Ekaterina has led teams in both academic and commercial settings, specializing in drug discovery, patient subpopulation selection, and precision medicine applications using multi-omics approaches, network, and pathway analysis. She has been actively involved in establishing partnerships with interdisciplinary teams and has made significant contributions to grant applications and deliveries.

Driven by her passion for translational medicine, Ekaterina co-founded a company dedicated to NGS-based cancer treatment predictions. Working closely with molecular oncologists, bioinformaticians, and systems biologists, the company focused on the application of systems biology to precision medicine, benefiting from seed investments and grants.

Ekaterina plays a crucial role in client-facing activities and business development, conducting client needs assessments, exploring market opportunities, proposing innovative solutions, and successfully overseeing project management across various therapy areas, including oncology, neuromuscular, skin, rare, and autoimmune diseases.

Latest news

News July 10, 2026
Clarivate to Report Second Quarter 2026 Results on July 29, 2026

London, U.K., July 10, 2026 – (PR Newswire) – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the second…

News July 9, 2026
Clarivate Releases G20 Research and Innovation Scorecard 2026

Tracking global research power, impact and collaboration as G20 priorities shift

News July 6, 2026
Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

Transaction sharpens company’s focus on AI-driven transformative intelligence for its leading Academia & Government and Intellectual Property segments Enhances financial profile by improving revenue mix, expanding Adjusted EBITDA margin and…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.